Q4 2021 Results
Participants
Company overview
Pharmaceuticals
Financial performance
Oncology
Innovation: Pipeline overview
Financial review
Conclusion
Appendix
Innovation: Clinical trials
Key milestones of pipeline assets with significant sales potential
with approval by 2026
Selected assets, most advanced and key indication(s) approved by 2026
High strength of evidence
Iptacopan PNH
2024
2025
2026
High strength of evidence
Iptacopan C3G
Iptacopan aHUS
Iptacopan IgAn
Remibrutinib CSU
Remibrutinib MS
Zolgensma SMA IT
Ligelizumab CSU
Ligelizumab CINDU
Ligelizumab Food Allergy
Kisqali
YTB323 2L DLBCL
lanalumab Sjögren's
2022
Ph3 readout
2023
Submission
Ensovibep COVID
2022
Submission
2023
2024
2025
2026
Ph3 read/sub
Scemblix
Approval
Ph3 readout Submission
Scemblix CML 1L
Ph3 readout
Submission
Ph3 read/sub
Alpelisib PROS
Approval
Ph3 read/sub
Piqray Ovarian Cancer
Ph3 read/sub
Piqray TNBC
Ph3 read/sub
Ph3 read/sub
Ph3 readout
Submission
Piqray HER2+ adv BC
Ph3 read/sub
Ph3 data in evaluation
Tislelizumab
Submissions and approvals of several indications
Ph3 readout
Submission
Ph3 read/sub
Ph3 readout¹
Submission
Ph3 start
Ph3 read/sub
Ph3 start
lanalumab LN
Ph3 start
Cosentyx HS
Submission
Cosentyx Lichen Planus
Ph2 readout
Cosentyx AS H2H
Ph3 readout
Submission
Cosentyx GCA
Ph3 read/sub
177 Lu-PSMA-617 mCRPCR post tax
Approval
177 Lu-PSMA-617 mCRPCR pre tax
177 Lu-PSMA-617 mHSPC
Ph3 readout¹
Submission
Ph3 read/sub
NME Lead
1. Event driven, could move to early 2023.
56 Investor Relations | Q4 2021 Results
Submission
Moderate strength of evidence
Sabatolimab MDS
2022
Ph2 readout
2023
2024
2025
2026
Sabatolimab AML
Ph3 readout
Ph3 readout
Submission in 2022/23
Submission
Ph3 read/sub
NIS793 PDAC
Ph3 read/sub
Ph3 read/sub
Pelacarsen CVRR
Ph3 read/sub
Canakinumab Adj. NSCLC
Ph3 readout
Submission
Ociperlimab
UNR844 Presbyopia
Ph3 start
Ph2 readout
BeiGene option deal
Submission
Libvatrep COSP
Ph2 readout
Submission
JDQ443 NSCLC
JDQ443+TNO155 NSCLC
Ph3 start
Submission
Ph3 start
Submission
✓ NOVARTIS | Reimagining MedicineView entire presentation